All Comments by Lon S. Schneider

  1. Paper Alert: Aducanumab Phase 1b Study Published
  2. Falling Dementia Rates in U.S. and Europe Sharpen Focus on Lifestyle
  3. A New Drug to Calm Agitation, Uncontrollable Laughing and Crying, in Alzheimer’s?
  4. Drug Appears Safe in Huntington’s; Experts Split on Functional Benefit
  5. No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
  6. Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation.
  7. Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor
  8. Phoenix: Making Trials Work for Patient, Sponsor, Regulator
  9. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis.
  10. Effect of short-term exposure to dichlorvos on synaptic plasticity of rat hippocampal slices: involvement of acylpeptide hydrolase and alpha(7) nicotinic receptors.
  11. Tarenflurbil protection from cytotoxicity is associated with an upregulation of neurotrophins.
  12. Effect of a short- and long-term treatment with Ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease.
  13. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake.
  14. Leon Thal Symposium Webinar
  15. Breakthrough or False Hope? Etanercept Case Report Draws Scrutiny